Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALM-PAH: Treprostinil Palmitil Inhalation Powder in Pulmonary Arterial Hypertension
NCT07481981Phase 3Recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 8
01
Overview
A Phase 3 trial of treprostinil palmitil in pulmonary arterial hypertension (PAH), sponsored by Insmed Incorporated. Started Jul 2026; status: recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07481981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481981.